Biotest Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Peter Janssen

Chief executive officer

€926.0k

Total compensation

CEO salary percentage	47.5%
CEO tenure	2.2yrs
CEO ownership	n/a
Management average tenure	2.8yrs
Board average tenure	2.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Peter Janssen's remuneration changed compared to Biotest's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	€41m
Jun 30 2024	n/a	n/a	€164m
Mar 31 2024	n/a	n/a	€177m
Dec 31 2023	€926k	€440k	€127m
Sep 30 2023	n/a	n/a	€119m
Jun 30 2023	n/a	n/a	-€10m
Mar 31 2023	n/a	n/a	-€47m
Dec 31 2022	€333k	€147k	-€32m

Compensation vs Market: Peter's total compensation ($USD970.65K) is below average for companies of similar size in the German market ($USD1.63M).

Compensation vs Earnings: Peter's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

CEO

Peter Janssen (56 yo)

2.2yrs

Tenure

€926,000

Compensation

Mr. Peter Janssen serves as Member of Management Board for Biotest Aktiengesellschaft since September 1, 2022 and served as its Chief Operating Officer since September 2022 until January 2024. He has been...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Peter Janssen	CEO & Chairman of the Board of Management	2.2yrs	€926.00k	no data
Dirk Schuck	Member of Supervisory Board	2.8yrs	€44.00k	no data
Monika Buttkereit	Head of Investor Relations	no data	no data	no data
Christina Erb	Head of Corporate HR	9.3yrs	no data	no data
Martin Möller	Group Finance and Treasury	no data	no data	no data

2.8yrs

Average Tenure

Experienced Management: BIO3's management team is considered experienced (2.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Dirk Schuck	Member of Supervisory Board	2.5yrs	€44.00k	no data
Raimon Grifols Roura	Member of Supervisory Board	1.5yrs	€29.00k	no data
Bernhard R. Ehmer	Chairman of the Supervisory Board	2.5yrs	€132.00k	no data
David Bell	Member of Supervisory Board	2.4yrs	€44.00k	no data
Jurgen Heilmann	Employee Representative Member of Supervisory Board	13.2yrs	€44.00k	no data

2.5yrs

Average Tenure

64.5yo

Average Age

Experienced Board: BIO3's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.

Biotest Management

Management criteria checks 2/4

Key information

Recent management updates

Biotest Aktiengesellschaft, Annual General Meeting, May 07, 2024

Biotest AG Appoints Peter Janssen as Chairman of the Management Board, Effective from January 1, 2024

Biotest AG Appoints Ainhoa Mendizabal as CFO, with Effect from 15 February, 2023

Biotest AG Announces Board Changes

Recent updates

Third quarter 2024 earnings released

Biotest Aktiengesellschaft to Report Fiscal Year 2024 Results on Mar 28, 2025

Second quarter 2024 earnings released: EPS: €0.24 (vs €0.075 loss in 2Q 2023)

Biotest Aktiengesellschaft to Report Q2, 2024 Results on Aug 06, 2024

Biotest Receives FDA Approval for Innovative Yimmugo Immunoglobulin to Treat Primary Immunodeficiencies

First quarter 2024 earnings released: EPS: €0.74 (vs €0.53 loss in 1Q 2023)

Upcoming dividend of €0.08 per share

New major risk - Revenue and earnings growth

Full year 2023 earnings: Revenues exceed analyst expectations

Biotest Aktiengesellschaft, Annual General Meeting, May 07, 2024

Biotest Aktiengesellschaft to Report First Half, 2024 Results on Jul 30, 2024

Biotest Aktiengesellschaft to Report Fiscal Year 2023 Results on Mar 28, 2024

Third quarter 2023 earnings released

Biotest Aktiengesellschaft Raises Earnings Guidance for the Year 2023

Biotest AG Appoints Peter Janssen as Chairman of the Management Board, Effective from January 1, 2024

New major risk - Financial position

Biotest Treats First Patient with Severe Community- Acquired Pneumonia in Phase III Trial with Trimodulin

Biotest AG Announces US Food and Drug Administration Accepts Marketing Authorization Application for Immunoglobulin Yimmugo

Second quarter 2023 earnings released: EPS: €0.55 (vs €0.39 loss in 2Q 2022)

First quarter 2023 earnings released

Full year 2022 earnings: Revenues miss analyst expectations

Now 20% undervalued after recent price drop

Biotest AG Appoints Ainhoa Mendizabal as CFO, with Effect from 15 February, 2023

Biotest Aktiengesellschaft to Report Fiscal Year 2022 Results on Mar 23, 2023

Third quarter 2022 earnings released

No longer forecast to breakeven

Second quarter 2022 earnings released: €0.39 loss per share (vs €0.11 loss in 2Q 2021)

Biotest AG Conducts Clinical Phase III Study PreCyssion with Cmv Hyperimmunoglobulin (Cytotect CP Biotest-) for the Prevention of CMV Infection in the Unborn Child in Germany

Biotest AG Achieves Important Milestone in Phase III Study in Acquired Fibrinogen Deficiency

First quarter 2022 earnings: Revenues in line with analyst expectations

Biotest AG Announces Board Changes

Upcoming dividend of €0.04 per share

Grifols, S.A. (BME:GRF) completed the acquisition of a 45.48% stake in Biotest Aktiengesellschaft (XTRA : BIO3) from Tiancheng International Investment Limited.

Biotest Submits Marketing Authorisation Application for IgG Next Generation

Consensus forecasts updated

Biotest AG Announces Biotest Treats First CMV-Positive Pregnant Woman in Phase III Clinical Trial to Prevent Transmission of CMV Infection to the Unborn Child

Consensus forecasts updated

Biotest AG Accelerates Trimodulin Development in Hospitalized Covid-19 Patients with Federal Funding from the German Ministries of Health, and Education & Research

Price target increased to €38.93

Third quarter 2021 earnings released

Biotest Receives Approval for Phase III Clinical Trial in Pregnant Women for Prevention of CMV Infection of the Unborn Baby

Biotest Announces the Outcome for Its ESsCOVID (Escape from Severe COVID-19) Trial in Patients with Severe COVID-19

Second quarter 2021 earnings released: €0.11 loss per share (vs €0.16 loss in 2Q 2020)

Biotest AG Provides Earnings Guidance for the Year 2021

Biotest AG Successfully Completes Recruitment for Its Clinical Trial with Trimodulin in Severe Covid-19 Patients

First quarter 2021 earnings released: €0.37 loss per share (vs €0.28 loss in 1Q 2020)

Upcoming dividend of €0.04 per share

Full year 2020 earnings released: €0.80 loss per share (vs €0.13 loss in FY 2019)

Consensus forecasts updated

Biotest Aktiengesellschaft Provides Earnings Guidance for the Year 2021

Biotest AG Supports Clinical Study with Pentaglobin(R) in Covid-19 at the University Hospital Akh Vienna

Biotest AG Revised Earnings Guidance for the Fiscal Year 2020

New 90-day high: €28.80

Biotest Aktiengesellschaft to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day high: €28.50

Biotest Aktiengesellschaft Announces Approval of Biotest Aktiengesellschaft for the Treatment of Severe Bacterial Infections with Concomitant Use of Antibiotics

Biotest Aktiengesellschaft to Report Q1, 2021 Results on May 11, 2021

Third quarter 2020 earnings released: €0.39 loss per share

Analysts update estimates

New 90-day high - €24.90

First half earnings released

New 90-day high - €22.30

New 90-day high - €21.30

Biotest Aktiengesellschaft to Report Q2, 2020 Results on Aug 13, 2020

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members